60
Participants
Start Date
September 1, 2025
Primary Completion Date
November 30, 2026
Study Completion Date
February 28, 2027
Efsubaglutide Alfa Injection
Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.
Diet and exercise guidelines
Participants followed a science-based diet and exercise program intervention.
RECRUITING
Nanjing Drum Tower Hospital, Nanjing
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER